Taro Corporate
Taro U.S.A
Taro Canada
Taro Israel
Sun Pharma
Chattem Chemicals Inc.
Taro RX product details
Product Information
-
DIN:02524058
-
Active Ingredients :sunitinib malate
-
Innovator Name:SUTENT®
-
Category:Tyrosine Kinase Inhibitor, Anti-Tumour Agent
-
Dosage form:Capsule
-
Strength:12.5 mg
-
Route of Administration:Oral
- Package size:
28 Bottle 30 Blister - UPC Code:
063691101425 063691101449 -
Description :Hard gelatin capsule with opaque reddish brown cap and opaque reddish brown body, self-lock capsule, imprinted with “RM53” on cap and “RM53” on body in white ink, containing yellow to orange colored powder.
-
Non-medicinal ingredients :croscarmellose sodium, magnesium stearate, mannitol and povidone. Capsule shell ingredients: iron oxide black (25 mg and 50 mg), iron oxide red (12.5 mg, 25 mg and 50 mg), iron oxide yellow (25 mg, 37.5 mg and 50 mg), gelatin and titanium dioxide. Imprinting Ink composition: iron oxide black (37.5 mg), potassium hydroxide, propylene glycol, shellac and titanium dioxide (12.5 mg, 25 mg, and 50 mg).
All brand names and trademarks referenced remain the property of their respective owners.
To view the available Product Monographs for Taro Pharmaceuticals Inc. and TaroPharma products please click here to access the Health Canada Drug Product Database and search by DIN or other listed criteria. You may also contact us to request the information.
For Provincial Formulary Status click here
Product Information
-
DIN:02524066
-
Active Ingredients :sunitinib malate
-
Innovator Name:SUTENT®
-
Category:Antineoplastic
-
Dosage form:Capsule
-
Strength:25 mg
-
Route of Administration:Oral
- Package size:
28 Bottle 30 Blister - UPC Code:
063691101456 063691101470 -
Description :Hard gelatin capsule with opaque caramel cap and opaque reddish brown body, self-lock capsule, imprinted with “RM54” on cap and “RM54” on body in white ink, containing yellow to orange colored powder.
-
Non-medicinal ingredients :croscarmellose sodium, magnesium stearate, mannitol and povidone. Capsule shell ingredients: iron oxide black (25 mg and 50 mg), iron oxide red (12.5 mg, 25 mg and 50 mg), iron oxide yellow (25 mg, 37.5 mg and 50 mg), gelatin and titanium dioxide. Imprinting Ink composition: iron oxide black (37.5 mg), potassium hydroxide, propylene glycol, shellac and titanium dioxide (12.5 mg, 25 mg, and 50 mg).
All brand names and trademarks referenced remain the property of their respective owners.
To view the available Product Monographs for Taro Pharmaceuticals Inc. and TaroPharma products please click here to access the Health Canada Drug Product Database and search by DIN or other listed criteria. You may also contact us to request the information.
For Provincial Formulary Status click here
Product Information
-
DIN:02524082
-
Active Ingredients :sunitinib malate
-
Innovator Name:SUTENT®
-
Category:Antineoplastic
-
Dosage form:Capsule
-
Strength:50 mg
-
Route of Administration:Oral
- Package size:
28 Bottle 30 Blister - UPC Code:
063691101517 063691101531 -
Description :Hard gelatin capsule with opaque caramel cap and opaque caramel body, self-lock capsule, imprinted with “RM56” on cap and “RM56” on body in white ink, containing yellow to orange colored powder.
-
Non-medicinal ingredients :croscarmellose sodium, magnesium stearate, mannitol and povidone. Capsule shell ingredients: iron oxide black (25 mg and 50 mg), iron oxide red (12.5 mg, 25 mg and 50 mg), iron oxide yellow (25 mg, 37.5 mg and 50 mg), gelatin and titanium dioxide. Imprinting Ink composition: iron oxide black (37.5 mg), potassium hydroxide, propylene glycol, shellac and titanium dioxide (12.5 mg, 25 mg, and 50 mg).
All brand names and trademarks referenced remain the property of their respective owners.
To view the available Product Monographs for Taro Pharmaceuticals Inc. and TaroPharma products please click here to access the Health Canada Drug Product Database and search by DIN or other listed criteria. You may also contact us to request the information.
For Provincial Formulary Status click here
